MTORC1 promotes denervation-induced muscle atrophy through a mechanism involving the activation of FoxO and E3 ubiquitin ligases

Science Signaling

Volumn 7, Issue 314, 2014, Pages

  Tang, Huibin ^a,b   Inoki, Ken ^c   Lee, Myung ^a,b   Wright, Erika ^a,b   Khuong, Andy ^a   Khuong, Amanda ^a   Sugiarto, Sista ^a   Garner, Matthew ^a   Paik, Jihye ^d   DePinho, Ronald A ^e   Goldman, Daniel ^f   Guan, Kun Liang ^g   Shrager, Joseph B ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROGIN 1; ISOPROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MUSCLE RING FINGER 1 PROTEIN; PHOSPHATIDIC ACID; PHOSPHOLIPASE D; PROTEIN; PROTEIN KINASE B; RAPAMYCIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FOXO; TUBEROUS SCLEROSIS COMPLEX 1; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CATABOLISM; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FAST MUSCLE; FEMALE; GENE DELETION; GENE EXPRESSION; HEREDITARY MOTOR SENSORY NEUROPATHY; MALE; MOUSE; MUSCLE DENERVATION; MUSCLE METABOLISM; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SOLEUS MUSCLE;

ANIMALS; DENERVATION; FORKHEAD TRANSCRIPTION FACTORS; GENE DELETION; MICE; MICE, TRANSGENIC; MULTIPROTEIN COMPLEXES; MUSCLE PROTEINS; MUSCULAR ATROPHY; PROTO-ONCOGENE PROTEINS C-AKT; SKP CULLIN F-BOX PROTEIN LIGASES; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 84895473275     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2004809     Document Type: Article

References (64)

1. R. W. Orrell, Motor neuron disease: Systematic reviews of treatment for ALS and SMA. Br. Med. Bull. 93, 145-159 (2010).
2. K. C. Kanning, A. Kaplan, C. E. Henderson, Motor neuron diversity in development and disease. Annu. Rev. Neurosci. 33, 409-440 (2010).
3. P. Bonaldo, M. Sandri, Cellular and molecularmechanisms ofmuscle atrophy. Dis. Model. Mech. 6, 25-39 (2013).
4. D. J. Glass, PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. Curr. Top. Microbiol. Immunol. 346, 267-278 (2010).
5. C. A. Goodman, D. L. Mayhew, T. A. Hornberger, Recent progress toward understanding the molecular mechanisms that regulate skeletal muscle mass. Cell. Signal. 23, 1896-1906 (2011).
6. S. M. Greising, H. M. Gransee, C. B. Mantilla, G. C. Sieck, Systems biology of skeletal muscle: Fiber type as an organizing principle. Wiley Interdiscip. Rev. Syst. Biol. Med. 4, 457-473 (2012).
7. W. E. Mitch, A. L. Goldberg, Mechanisms of muscle wasting-The role of the ubiquitin-proteasome pathway. N. Engl. J. Med. 335, 1897-1905 (1996). (Pubitemid 26419198)
8. R. W. Jackman, S. C. Kandarian, The molecular basis of skeletal muscle atrophy. Am. J. Physiol. Cell Physiol. 287, C834-C843 (2004). (Pubitemid 39238306)
9. S.C. Bodine, E. Latres, S. Baumhueter,V. K. Lai, L.Nunez, B. A.Clarke,W. T. Poueymirou, F. J. Panaro,E.Na, K.Dharmarajan, Z.Q. Pan, D. M.Valenzuela, T.M.DeChiara, T. N. Stitt, G. D. Yancopoulos,D. J.Glass, Identification of ubiquitin ligases required for skeletalmuscle atrophy. Science 294, 1704-1708 (2001a). (Pubitemid 33104839)
10. M. D. Gomes, S. H. Lecker, R. T. Jagoe, A. Navon, A. L. Goldberg, Atrogin-1, a musclespecific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci. U.S.A. 98, 14440-14445 (2001). (Pubitemid 33121410)
11. S. H. Lecker, R. T. Jagoe, A. Gilbert, M. Gomes, V. Baracos, J. Bailey, S. R. Price, W. E. Mitch, A. L. Goldberg, Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18, 39-51 (2004). (Pubitemid 38076464)
12. B. C. Beehler, P. G. Sleph, L. Benmassaoud, G. J. Grover, Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation. Exp. Biol. Med. 231, 335-341 (2006). (Pubitemid 43334321)
13. T. J. Cohen, D. S. Waddell, T. Barrientos, Z. Lu, G. Feng, G. A. Cox, S. C. Bodine, T. P. Yao, The histone deacetylase HDAC4 connects neural activity to muscle transcriptional reprogramming. J. Biol. Chem. 282, 33752-33759 (2007). (Pubitemid 350159508)
14. H. Tang, D. Goldman, Activity-dependent gene regulation in skeletal muscle is mediated by a histone deacetylase (HDAC)-Dach2-myogenin signal transduction cascade. Proc. Natl. Acad. Sci. U.S.A. 103, 16977-16982 (2006). (Pubitemid 44737363)
15. H. Tang, P. Macpherson, M. Marvin, E. Meadows, W. H. Klein, X. J. Yang, D. Goldman, A histone deacetylase 4/myogenin positive feedback loop coordinates denervationdependent gene induction and suppression. Mol. Biol. Cell 20, 1120-1131 (2009).
16. V. Moresi, A. H. Williams, E. Meadows, J. M. Flynn, M. J. Potthoff, J. McAnally, J. M. Shelton, J. Backs, W. H. Klein, J. A. Richardson, R. Bassel-Duby, E. N. Olson, Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. Cell 143, 35-45 (2010).
17. P. C. Macpherson, X. Wang, D. Goldman, Myogenin regulates denervation-dependent muscle atrophy in mouse soleus muscle. J. Cell. Biochem. 112, 2149-2159 (2011).
18. M. Sandri, C. Sandri, A. Gilbert, C. Skurk, E. Calabria, A. Picard, K. Walsh, S. Schiaffino, S. H. Lecker, A. L. Goldberg, Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117, 399-412 (2004). (Pubitemid 38534545)
19. Y. Kamei, S. Miura, M. Suzuki, Y. Kai, J. Mizukami, T. Taniguchi, K. Mochida, T. Hata, J. Matsuda, H. Aburatani, I. Nishino, O. Ezaki, Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J. Biol. Chem. 279, 41114-41123 (2004). (Pubitemid 39287713)
20. S. M. Senf, S. L. Dodd, A. R. Judge, FOXO signaling is required for disuse muscle atrophy and is directly regulated by Hsp70. Am. J. Physiol. Cell Physiol. 298, C38-C45 (2010).
21. S. A. Reed, P. B. Sandesara, S. M. Senf, A. R. Judge, Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy. FASEB J. 26, 987-1000 (2012).
22. C. C. Thoreen, L. Chantranupong, H. R. Keys, T. Wang, N. S. Gray, D. M. Sabatini, A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485, 109-113 (2012).
23. M. Laplante, D. M. Sabatini, mTOR signaling in growth control and disease. Cell 149, 274-293 (2012).
24. E. Dazert,M.N.Hall,mTORsignaling in disease. Curr. Opin.CellBiol. 23, 744-755 (2011).
25. D. A. Guertin, D. M. Sabatini, Defining the role of mTOR in cancer. Cancer Cell 12, 9-22 (2007). (Pubitemid 47001784)
26. A.C. Hsieh, Y. Liu, M. P. Edlind,N. T. Ingolia,M. R. Janes, A.Sher, E. Y. Shi,C. R. Stumpf, C. Christensen, M. J. Bonham, S. Wang, P. Ren, M. Martin, K. Jessen, M. E. Feldman, J. S. Weissman, K. M. Shokat, C. Rommel, D. Ruggero, The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485, 55-61 (2012).
27. C. F. Bentzinger, K. Romanino, D. Cloëtta, S. Lin, J. B. Mascarenhas, F. Oliveri, J. Xia, E. Casanova, C. F. Costa, M. Brink, F. Zorzato, M. N. Hall, M. A. Rüegg, Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab. 8, 411-424 (2008).
28. K. G. Foster, H. A. Acosta-Jaquez, Y. Romeo, B. Ekim, G. A. Soliman, A. Carriere, P. P. Roux, B. A. Ballif, D. C. Fingar, Regulation of mTOR complex 1 (mTORC1) by raptor Ser863 and multisite phosphorylation. J. Biol. Chem. 285, 80-94 (2010).
29. K. Inoki, H. Mori, J. Wang, T. Suzuki, S. Hong, S. Yoshida, S. M. Blattner, T. Ikenoue, M. A. Rüegg, M. N. Hall, D. J. Kwiatkowski, M. P. Rastaldi, T. B. Huber, M. Kretzler, L. B. Holzman, R. C. Wiggins, K. L. Guan, mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J. Clin. Invest. 121, 2181-2196 (2011).
30. V. Risson, L.Mazelin,M.Roceri, H.Sanchez,V.Moncollin, C.Corneloup,H.Richard-Bulteau, A. Vignaud, D. Baas, A. Defour, D. Freyssenet, J. F. Tanti, Y. Le-Marchand-Brustel, B. Ferrier, A.Conjard-Duplany, K. Romanino, S. Bauché,D.Hantaï,M.Mueller, S.C. Kozma, G. Thomas, M. A. Rüegg, A. Ferry, M. Pende, X. Bigard, N. Koulmann, L. Schaeffer, Y. G. Gangloff, Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy. J. Cell Biol. 187, 859-874 (2009).
31. M. Wan, X. Wu, K. L. Guan, M. Han, Y. Zhuang, T. Xu, Muscle atrophy in transgenic mice expressing a human TSC1 transgene. FEBS Lett. 580, 5621-5627 (2006). (Pubitemid 44498663)
32. V. Aguilar, S. Alliouachene, A. Sotiropoulos, A. Sobering, Y. Athea, F. Djouadi, S. Miraux, E. Thiaudière, M. Foretz, B. Viollet, P. Diolez, J. Bastin, P. Benit, P. Rustin, D. Carling, M. Sandri, R. Ventura-Clapier, M. Pende, S6 kinase deletion suppresses muscle growth adaptations to nutrient availability by activating AMP kinase. Cell Metab. 5, 476-487 (2007). (Pubitemid 46825498)
33. V. Mieulet, M. Roceri, C. Espeillac, A. Sotiropoulos, M. Ohanna, V. Oorschot, J. Klumperman, M. Sandri, M. Pende, S6 kinase inactivation impairs growth and translational target phosphorylation in muscle cells maintaining proper regulation of protein turnover. Am. J. Physiol. Cell Physiol. 293, C712-C722 (2007). (Pubitemid 47235195)
34. M. Machida, K. Takeda, H. Yokono, S. Ikemune, Y. Taniguchi, H. Kiyosawa, T. Takemasa, Reduction of ribosome biogenesis with activation of the mTOR pathway in denervated atrophic muscle. J. Cell. Physiol. 227, 1569-1576 (2012).
35. H. M. Argadine, C. B. Mantilla, W. Z. Zhan, G. C. Sieck, Intracellular signaling pathways regulating net protein balance following diaphragm muscle denervation. Am. J. Physiol. Cell Physiol. 300, C318-C327 (2011).
36. D. M. Sabatini, mTOR and cancer: Insights into a complex relationship. Nat. Rev. Cancer 6, 729-734 (2006). (Pubitemid 44286004)
37. J. Zhang, Z. Gao, J. Yin, M. J. Quon, J. Ye, S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-a signaling through IKK2. J. Biol. Chem. 283, 35375-35382 (2008).
38. A. Takano, I. Usui, T. Haruta, J. Kawahara, T. Uno, M. Iwata, M. Kobayashi, Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Mol. Cell. Biol. 21, 5050-5062 (2001). (Pubitemid 32656402)
39. F. Tremblay, A. Marette, Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J. Biol. Chem. 276, 38052-38060 (2001).
40. A.C. Gingras, B.Raught, S.P. Gygi,A.Niedzwiecka,M.Miron,S.K.Burley, R.D. Polakiewicz, A. Wyslouch-Cieszynska, R. Aebersold, N. Sonenberg, Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15, 2852-2864 (2001). (Pubitemid 33042055)
41. D. Shahbazian, P. P. Roux, V.Mieulet,M. S.Cohen, B. Raught, J. Taunton, J.W. Hershey, J. Blenis, M. Pende, N. Sonenberg, The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J. 25, 2781-2791 (2006). (Pubitemid 43980385)
42. J. Ling, S. J. Morley, J. A. Traugh, Inhibition of cap-dependent translation via phosphorylation of eIF4G by protein kinase Pak2. EMBO J. 24, 4094-4105 (2005). (Pubitemid 41752878)
43. T. A. Hornberger, Mechanotransduction and the regulation of mTORC1 signaling in skeletal muscle. Int. J. Biochem. Cell Biol. 43, 1267-1276 (2011).
44. T. A. Hornberger, W. K. Chu, Y. W. Mak, J. W. Hsiung, S. A. Huang, S. Chien, The role of phospholipase D and phosphatidic acid in the mechanical activation of mTOR signaling in skeletal muscle. Proc. Natl. Acad. Sci. U.S.A. 103, 4741-4746 (2006).
45. C. F. Bentzinger, S. Lin, K. Romanino, P. Castets, M. Guridi, S. Summermatter, C. Handschin, L. A. Tintignac, M. N. Hall, M. A. Rüegg, Differential response of skeletal muscles tomTORC1 signaling during atrophy and hypertrophy. Skelet.Muscle 3, 6 (2013).
46. P. Castets, S. Lin, N. Rion, S. Di Fulvio, K. Romanino, M. Guridi, S. Frank, L. A. Tintignac, M. Sinnreich, M. A. Rüegg, Sustained activation of mTORC1 in skeletal muscle inhibits constitutive and starvation-induced autophagy and causes a severe, late-onset myopathy. Cell Metab. 17, 731-744 (2013).
47. C. H. Lee, K. Inoki, K. L. Guan, mTOR pathway as a target in tissue hypertrophy. Annu. Rev. Pharmacol. Toxicol. 47, 443-467 (2007).
48. A. Suryawan, J. Escobar, J. W. Frank, H. V. Nguyen, T. A. Davis, Developmental regulation of the activation of signaling components leading to translation initiation in skeletal muscle of neonatal pigs. Am. J. Physiol. Endocrinol. Metab. 291, E849-E859 (2006). (Pubitemid 44484929)
49. S. C. Bodine, T. N. Stitt,M.Gonzalez,W. O. Kline, G. L. Stover, R. Bauerlein, E. Zlotchenko, A. Scrimgeour, J. C. Lawrence, D. J. Glass, G. D. Yancopoulos, Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 3, 1014-1019 (2001). (Pubitemid 34428747)
50. D. E. Harrison, R. Strong, Z. D. Sharp, J. F. Nelson, C. M. Astle, K. Flurkey, N. L. Nadon, J. E. Wilkinson, K. Frenkel, C. S. Carter, M. Pahor, M. A. Javors, E. Fernandez, R. A. Miller, Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392-395 (2009).
51. X. Zhang, L. Li, S. Chen, D. Yang, Y. Wang, Z. Wang, W. Le, Rapamycin treatment augments motor neuron degeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis. Autophagy 7, 412-425 (2011).
52. T. N. Stitt, D. Drujan, B. A. Clarke, F. Panaro, Y. Timofeyva, W. O. Kline, M. Gonzalez, G. D. Yancopoulos, D. J. Glass, The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell 14, 395-403 (2004). (Pubitemid 38591410)
53. S. Schiaffino, C. Mammucari, Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: Insights from genetic models. Skelet. Muscle 1, 4 (2011).
54. P. C. Schulze, J. Fang, K. A. Kassik, J. Gannon, M. Cupesi, C. MacGillivray, R. T. Lee, N. Rosenthal, Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction. Circ. Res. 97, 418-426 (2005). (Pubitemid 41298171)
55. C.Rommel, S. C.Bodine, B. A. Clarke,R.Rossman, L. Nunez,T.N.Stitt, G.D.Yancopoulos, D. J. Glass, Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3, 1009-1013 (2001). (Pubitemid 34428746)
56. Y. Nabeshima, K. Hanaoka, M. Hayasaka, E. Esumi, S. Li, I. Nonaka, Myogenin gene disruption results in perinatal lethality because of severe muscle defect. Nature 364, 532-535 (1993). (Pubitemid 23273098)
57. P. Hasty, A. Bradley, J. H.Morris, D. G. Edmondson, J. M. Venuti, E. N. Olson, W. H. Klein, Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene. Nature 364, 501-506 (1993). (Pubitemid 23273093)
58. J. R. Knapp, J. K. Davie, A. Myer, E. Meadows, E. N. Olson, W. H. Klein, Loss of myogenin in postnatal life leads to normal skeletal muscle but reduced body size. Development 133, 601-610 (2006).
59. P. P. Hsu, S. A. Kang, J. Rameseder, Y. Zhang, K. A. Ottina, D. Lim, T. R. Peterson, Y. Choi, N. S. Gray, M. B. Yaffe, J. A. Marto, D. M. Sabatini, The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-1322 (2011).
60. Y. Yu, S.O. Yoon,G. Poulogiannis,Q. Yang, X. M. Ma, J. Villén, N. Kubica,G. R. Hoffman, L. C. Cantley, S. P. Gygi, J. Blenis, Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322-1326 (2011).
61. T. Hosaka, W. H. Biggs, D. Tieu, A. D. Boyer, N. M. Varki, W. K. Cavenee, K. C. Arden, Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proc. Natl. Acad. Sci. U.S.A. 101, 2975-2980 (2004). (Pubitemid 38327721)
62. L. Meikle, J. R. McMullen, M. C. Sherwood, A. S. Lader, V. Walker, J. A. Chan, D. J. Kwiatkowski, A mouse model of cardiac rhabdomyoma generated by loss of Tsc1 in ventricular myocytes. Hum. Mol. Genet. 14, 429-435 (2005). (Pubitemid 40220660)
63. E. J. Uhlmann, M. Wong, R. L. Baldwin, M. L. Bajenaru, H. Onda, D. J. Kwiatkowski, K. Yamada, D. H. Gutmann, Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann. Neurol. 52, 285-296 (2002). (Pubitemid 35001494)
64. J. H. Paik, R. Kollipara, G. Chu, H. Ji, Y. Xiao, Z. Ding, L. Miao, Z. Tothova, J. W. Horner, D. R. Carrasco, S. Jiang, D. G. Gilliland, L. Chin,W. H.Wong, D. H. Castrillon, R. A. DePinho, FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128, 309-323 (2007). (Pubitemid 46123514)